Iron Overload in Children with Acute Lymphoblastic and Acute Myeloblastic Leukemia—Experience of One Center.

Simple Summary: Post-transfusion iron overload is a common side effect of anticancer treatment, including leukemias. We showed that serum ferritin levels could be valuable prognostic marker of death in children with AML and ALL. Importantly, improved survival of leukemia patients was found to be associated with lower ferritin values before therapy. It is noteworthy that the observed phenomenon was dependent on the cancer type, sex, and age of the studied patients. Transfusions of packed red blood cells (PRBCs), given due to an oncological disease and its acute complications, are an indispensable part of anticancer therapy. However, they can lead to post-transfusion iron overload. The study aim was to evaluate the role of ferritin as a nonspecific marker of leukemic growth and marker of transfusion-related iron overload. We performed a longitudinal study of PRBC transfusions and changes in ferritin concentrations during the oncological treatment of 135 patients with childhood acute lymphoblastic and acute myeloblastic leukemia (ALL and AML, median age 5.62 years). At the diagnosis, 41% of patients had a ferritin level over 500 ng/mL, and 14% of patients had a ferritin level over 1000 ng/mL. At the cessation of the treatment, 80% of the children had serum ferritin (SF) over 500 ng/mL, and 31% had SF over 1000 ng/mL. There was no significant difference between SF at the beginning of the treatment between ALL and AML patients, but children with AML finished treatment with statistically higher SF. AML patients had also statistically higher number of transfusions. We found statistically significant positive correlations between ferritin and age, and weight and units of transfused blood. Serum ferritin at the moment of diagnosis can be a useful marker of leukemic growth, but high levels of SF are connected with iron overload in both AML and ALL. [ABSTRACT FROM AUTHOR]